Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong

Summary

The purpose of this study is to assess the tolerability and safety of KRX-101 in treating persistent microalbuminuria in type 2 diabetic patients who are also being treated with stable, maximum tolerated doses of either ACE inhibitors or A2 receptor blockers.

Timeline

Start

2007-04

Primary completion

2008-03

Completion

2008-03

Drugs

Indications